InvestorsHub Logo

winnail

05/31/16 3:24 PM

#149614 RE: sox040713 #149611

Thanks,Sox-I mean MR.SOX- you are doing a really good job stating the FACTS-good work

TheHound

05/31/16 3:30 PM

#149616 RE: sox040713 #149611

Thanks Sox! And as BK has pointed out on more than one occasion,.....

What is in question are the elements of QIDP fast-rack that will be applied. At least one and possibly up to all of the following are possible and will result from the FDA Phase 2 meeting.

Accelerated review only. (Reduces the review time between trials from > 10 months to ~ 6 months)
Rolling review
Surrogate endpoints
FDA intensive guidance and organizational commitment
60 day FDA responses

The trifecta: rolling review with surrogate endpoints, intensive guidance and organizational commitment, 60 day BLA and NDA guaranteed response time.

Also, some of the elements depend on a sponsors ability to guarantee rapid marketing and product quality after approval. In CTIX's case that will require a partner or license.



http://investorshub.advfn.com/boards/replies.aspx?msg=115224134


Amatuer17

06/01/16 8:29 PM

#149722 RE: sox040713 #149611

Thanks

So basic question is - why Leo did not request FTD yet? What he is waiting for?